HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Flaxseed-derived enterolactone is inversely associated with tumor cell proliferation in men with localized prostate cancer.

Abstract
Enterolactone and enterodiol, mammalian lignans derived from dietary sources such as flaxseed, sesame seeds, kale, broccoli, and apricots, may impede tumor proliferation by inhibiting activation of nuclear factor kappa B (NFκB) and vascular endothelial growth factor (VEGF). We examined the associations between urinary enterolactone and enterodiol with prostatic tumor expression of NFκB, VEGF, and Ki67 among 147 patients with prostate cancer who participated in a presurgical trial of flaxseed supplementation (30 g/day) for ~30 days. Urinary enterolignans and tissue biomarkers were determined by high-performance liquid chromatography and immunohistochemistry, respectively. After supplementation, we observed significant correlations between intakes of plant lignan and urinary concentrations of total enterolignans (ρ=0.677, P<.0001), enterolactone (ρ=0.676, P<.0001), and enterodiol (ρ=0.628, P<.0001). Importantly, we observed that total urinary enterolignans and enterolactone were significantly and inversely correlated with Ki67 in the tumor tissue (ρ=-0.217, P=.011, and ρ=-0.230, P=.007, respectively), and a near-significant inverse association was observed for enterodiol (ρ=-0.159, P=.064). An inverse association was observed between enterolactone and VEGF (ρ=-0.143, P=.141), although this did not reach statistical significance. We did not observe an association between enterolignans and NFκB. In conclusion, flaxseed-derived enterolignans may hinder cancer cell proliferation via VEGF-associated pathways.
AuthorsMaria Azrad, Robin T Vollmer, John Madden, Mark Dewhirst, Thomas J Polascik, Denise C Snyder, Mack T Ruffin, Judd W Moul, Dean E Brenner, Wendy Demark-Wahnefried
JournalJournal of medicinal food (J Med Food) Vol. 16 Issue 4 Pg. 357-60 (Apr 2013) ISSN: 1557-7600 [Electronic] United States
PMID23566060 (Publication Type: Clinical Trial, Phase II, Journal Article, Randomized Controlled Trial, Research Support, N.I.H., Extramural)
Chemical References
  • Antineoplastic Agents, Phytogenic
  • Biomarkers
  • Ki-67 Antigen
  • Lignans
  • Plant Extracts
  • Vascular Endothelial Growth Factor A
  • 2,3-bis(3'-hydroxybenzyl)butane-1,4-diol
  • 4-Butyrolactone
  • 2,3-bis(3'-hydroxybenzyl)butyrolactone
Topics
  • 4-Butyrolactone (analogs & derivatives, pharmacology, therapeutic use, urine)
  • Aged
  • Antineoplastic Agents, Phytogenic (pharmacology, therapeutic use)
  • Biomarkers (metabolism, urine)
  • Cell Proliferation (drug effects)
  • Dietary Supplements
  • Flax (chemistry)
  • Humans
  • Ki-67 Antigen (metabolism)
  • Lignans (pharmacology, therapeutic use, urine)
  • Male
  • Middle Aged
  • Phytotherapy
  • Plant Extracts (pharmacology, therapeutic use)
  • Prostatic Neoplasms (drug therapy, metabolism, urine)
  • Vascular Endothelial Growth Factor A (metabolism)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: